Outcome of patients with advanced non-transitional urothelial carcinomas following platinum-based chemotherapy

Kastritis, E.; Bozas, George; Efstathiou, Eleni; Koutsoukou, Vasiliki; Gika, D; Deliveliotis, Ch.; Antoniou, N.; Dimopoulos, M. A.; Bamias, Aristotle

doi:10.1200/jco.2005.23.16_suppl.4596

Cited by 14 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The other chemotherapeutic regimens which were used as second-or third-line chemotherapies were as follows: [7] TC, paclitaxel and carboplatin; [8] EP, etoposide and cisplatin; [9] BOMP, bleomycin, vincristine, mitomycin, and cisplatin; [10] VI, VP-16 and ifosfamide; and [11] paclitaxel.…”

Section: Treatmentmentioning

confidence: 99%

“…Nevertheless, information on the efficacy of palliative chemotherapy for nontransitional cell carcinomas are extremely sparse, and there is no consensus about palliative chemotherapy for advanced non-transitional cell carcinomas of the urothelial tract. Some reports have suggested that non-transitional cell carcinomas may be more resistant to chemotherapy, but only small series of data exist addressing the outcome of palliative chemotherapy, thus far [8][9][10].…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract

et al. 2008

View full text Add to dashboard Cite

Non-transitional cell carcinomas of the urothelial tract comprise 5-10% of urothelial cancers. Clinical information regarding the clinical behavior and chemotherapy outcome of non-transitional cell carcinomas of the urothelial tract are incomplete due to their rarity. The object of this study was to evaluate the clinical features and the efficacy of palliative chemotherapy in advanced non-transitional cell carcinomas of the urothelial tract. We analyzed the clinical records of 21 consecutive patients who received palliative chemotherapy for unresectable or metastatic non-transitional cell carcinomas of the urothelial tract between January 1995 and November 2007. All the 21 patients received first-line chemotherapy with platinum-based regimens which are known to be effective in transitional cell urothelial carcinomas. The median age of the patients was 57 years (range, 27-71 years). The primary sites of involvement were the bladder, urethra, urachus, and ureter in 43%, 29%, 19%, and 10% of the patients, respectively. Adenocarcinoma was the most common histological type (67%); squamous cell carcinoma and small cell carcinoma comprised 24 and 10% of the histologic types, respectively. With a median duration of follow-up of 32 months (range, 12-71 months), the median overall survival for all 21 patients from the day of first-line chemotherapy was 13 months (95% CI, 6.8-19.2). The expected 1-year survival rate was 50.6% (95% CI, 28.6-72.5). Univariate analysis showed a better median overall survival in patients with adenocarcinoma, compared to non-adenocarcinomas (47 vs. 10 months, P = 0.049). The median overall survival of patients who received platinum-based palliative chemotherapy for advanced non-transitional cell carcinomas was comparable to previous studies for patients with transitional cell carcinomas. Adenocarcinomas appear to have a favorable prognosis for the survival of the patients who received platinum-based chemotherapy for advanced non-transitional cell carcinomas.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract

et al. 2008

View full text Add to dashboard Cite

show abstract

“…10 Mixed histological features are associated with a decreased response to systemic chemotherapy, 11 although a more contemporary series did not show inferior survival after platinum based chemotherapy for nonUC histology. 12 Also, a recent subset analysis of the SWOG directed intergroup randomized trial of neoadjuvant chemotherapy followed by cystectomy vs cystectomy alone showed that mixed histological features, specifically squamous or glandular differentiation, did not confer resistance to chemotherapy. 13 There was a suggestion that the survival benefit of chemotherapy in patients with mixed tumors was greater than in patients with pure UC.…”

mentioning

confidence: 98%

The Impact of Squamous and Glandular Differentiation on Survival After Radical Cystectomy for Urothelial Carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Both studies reported SQD to have similar responses to chemotherapy compared to the NV group. Similarly, Kastritis et al found that when treating advanced or metastatic urothelial carcinoma with a platinum-based chemotherapy regimen, SQD and NV bladder cancer exhibited similar responsiveness 16 . Lastly, in a secondary analysis of the SWOG S8710 clinical trial using neoadjuvant MVAC (methotrexate, vincristine, doxorubicin, and cisplatin), SQD demonstrated nonstatistically significant (p=0.09) improved survival benefit compared to NV in locally advanced urothelial carcinoma 14 .…”

Section: Discussionmentioning

confidence: 99%

“…Although SQD was previously shown to be associated with higher pathologic staging and increased risk of local recurrence, when accounting for stage, SQD does not alter overall survival (OS) or disease-specific survival (DSS) 7,8,[11][12][13] . Furthermore, there is evidence suggesting that SQD may be equally sensitive to chemotherapy as non-variant (NV) urothelial bladder cancer 10,12,[14][15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Does Squamous Differentiation Portend Worse Outcomes in Urothelial Bladder Cancer?

et al. 2015

View full text Add to dashboard Cite

Outcome of patients with advanced non-transitional urothelial carcinomas following platinum-based chemotherapy

Cited by 14 publications

References 0 publications

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract

The Impact of Squamous and Glandular Differentiation on Survival After Radical Cystectomy for Urothelial Carcinoma

Does Squamous Differentiation Portend Worse Outcomes in Urothelial Bladder Cancer?

Contact Info

Product

Resources

About